Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.124.039113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Chun-Ka Wong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ritonavir, COVID-19 Drug Treatment, COVID-19. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Concomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants (DOACs) for COVID‐19 is challenging due to potential drug–drug interactions. This study assessed the safety and effectiveness of nirmatrelvir/ritonavir compared with RNA‐dependent RNA polymerase inhibitors in patients with COVID‐19 and atrial fibrillation treated with a DOAC.
Methods
We conducted a territory‐wide retrospective study of patients with COVID‐19 hospitalized in Hong Kong between January and November 2022 for antiviral therapy who had atrial fibrillation managed with a DOAC. Clinical outcomes including 30‐day all‐cause death, ischemic stroke, myocardial infarction, and bleeding events were evaluated.
Results
Overall, 1297 (91%) patients were prescribed an RNA‐dependent RNA polymerase inhibitor, and 127 (9%), nirmatrelvir/ritonavir. Among patients treated with nirmatrelvir/ritonavir, 77 (60.6%) continued DOAC treatment, 30 (23.6%) switched to low‐molecular‐weight heparin, and 20 (15.7%) withheld anticoagulation therapy. After propensity score matching (n=1270), 1143 and 127 patients were in the RNA‐dependent RNA polymerase inhibitor and nirmatrelvir/ritonavir groups, respectively. On univariate analysis, the 30‐day all‐cause death was lower in the nirmatrelvir/ritonavir group (5.51% versus 12.1%; P =0.033). However, after adjusting for covariates including age and COVID‐19 severity, this difference was no longer statistically significant. The incidence of bleeding events was not significantly different between groups ( P =0.654), and there were no statistically significant differences in ischemic stroke, myocardial infarction, or need for ventilatory support.
Conclusions
In a territory‐wide cohort of hospitalized patients with COVID‐19 and atrial fibrillation on a DOAC, nirmatrelvir/ritonavir therapy was associated with lower unadjusted 30‐day all‐cause death compared with RNA‐dependent RNA polymerase inhibitors; however, this difference was not significant after adjusting for age and COVID‐19 severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China.
- Cardiac and Vascular Center The University of Hong Kong-Shenzhen Hospital Shenzhen China.
- Department of Statistics Chinese University of Hong Kong Hong Kong SAR China.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital Liverpool UK.
- Danish Center for Health Services Research, Department of Clinical Medicine Aalborg University Aalborg Denmark.
- Centre for Stem Cell Translational Biology Hong Kong SAR China.
ORCID-Profile: Chun-Ka Wong, Benjamin Yu-Fai So, Ho-On Alston Conrad Chiu, Frankie Chor-Cheung Tam, Minqing Lin, Wang-Chun Kwok, Wing-Ming Chu, Anthony R Tam, Fan-Ngai Hung, Gregory Y H Lip, Hung-Fat Tse
Zitieren
APA
Wong, C. K., So, B. Y., Leung, I. S., Choo, A., Chiu, H. A. C., Tam, F. C., Lin, M., Kwok, W. C., Lam, S. C., Chan, K. E., Un, K. C., Lam, T. H., Chu, W. M., Tam, A. R., Hung, F. N., Lip, G. Y. H., & Tse, H. F. (2026). Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039113
Vancouver
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, et al. Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation. Journal of the American Heart Association. 2026. doi:10.1161/jaha.124.039113
BibTeX
@article{Wong2026,
author = {Wong, Chun-Ka and So, Benjamin Yu-Fai and Leung, Isaac Sze-Him and Choo, Ali and Chiu, Ho-On Alston Conrad and Tam, Frankie Chor-Cheung and Lin, Minqing and Kwok, Wang-Chun and Lam, Simon Cheung-Chi and Chan, Kwong-Yue Eric and Un, Ka-Chun and Lam, Tsun-Ho and Chu, Wing-Ming and Tam, Anthony R and Hung, Fan-Ngai and Lip, Gregory Y H and Tse, Hung-Fat},
title = {Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID‐19 Among Patients With Atrial Fibrillation},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.124.039113}
}
EUVIMED